Liraglutide pharmacotherapy reduces body weight and improves glycemic control in juvenile obese / hyperglycemic male and female rats
ConclusionThese preclinical data suggest that maternal and early ‐life consumption of HFSD increases caloric intake, body weight gain and hyperglycemia, a collective set of unwanted metabolic effects that appear to be treatable in juveniles with liraglutide pharmacotherapy intervention.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Claudia G. Liberini,
Rinzin Lhamo,
Misgana Ghidewon,
Tyler Ling,
Nina Juntereal,
Jack Chen,
Anh Cao,
Lauren M. Stein,
Matthew R. Hayes Tags: ORIGINAL ARTICLE Source Type: research
More News: Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Nutrition | Obesity | Pregnancy | Victoza